Thursday, February 29, 2024
9:55 AM EST – Knight Therapeutics Inc., : Announced today the launch of Minjuvi® (tafasitamab) by its Brazilian affiliate, United Medical Ltda. Minjuvi® is indicated in combination with lenalidomide, followed by Minjuvi® monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant. Knight Therapeutics Inc.,
(T.GUD) shares were down $0.14 at 5.41.
Stocks in Play: Knight Therapeutics Inc.,, Thu, 29 Feb 2024 09:57:06 EST